Principles of minimal residual disease detection for hematopoietic neoplasms by flow cytometry

Cytometry Part B - Clinical Cytometry

Volumn 90, Issue 1, 2016, Pages 47-53

  Wood, Brent L ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

cytometry; leukemia; minimal; monitoring; residual

Indexed keywords

ACUTE MYELOID LEUKEMIA; B LYMPHOBLASTIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; FLOW CYTOMETRY; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA ASSOCIATED IMMUNOPHENOTYPE; LIMIT OF QUANTITATION; LYMPHATIC LEUKEMIA; MINIMAL RESIDUAL DISEASE; PROCESSING; REPRODUCIBILITY; REVIEW; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; T LYMPHOBLASTIC LEUKEMIA; BONE MARROW CELL; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; LYMPHOCYTE; MORTALITY; NEOPLASM, RESIDUAL; PATHOLOGY; PROGNOSIS; REMISSION; STANDARDS; SURVIVAL ANALYSIS;

ANTIBODY; ANTINEOPLASTIC AGENT; LEUKOCYTE ANTIGEN;

ANTIBODIES; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; FLOW CYTOMETRY; GENE EXPRESSION; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTES; NEOPLASM, RESIDUAL; PROGNOSIS; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS;

EID: 85011011304     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21239     Document Type: Review

References (43)

1. Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.Lyon, France: IARC Press; 2008.
2. Cherian S, Wood BL. Flow Cytometry in Evaluation of Hematopoietic Neoplasms: A Case Based Approach. CAP Press: Northfield, IL; 2012.
3. Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008;111:3941–3967.
4. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999;38:139–152.
5. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A children's oncology group study. Blood 2008;111:5477–5485.
6. Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, Mullighan CG, Zhou Y, Pui CH, Campana D. Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010;115:4657–4663.
7. Gaipa G, Basso G, Biondi A, Campana D. Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom 2013;84B:359–369.
8. Schrappe M, Valsecchi MG, Bartram CR, Schrauder A, Panzer-Grumayer R, Moricke A, Parasole R, Zimmermann M, Dworzak M, Buldini B, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: Results of the AIEOP-BFM-ALL 2000 study. Blood 2011;118:2077–2084.
9. Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, et al. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: Data from the HOVON/SAKK AML 42A study. J Clin Oncol 2013;31:3889–3897.
10. Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, Delaney C, Radich JP, et al. Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission. Blood 2013;122:1813–1821.
11. Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T. Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood 2004;104:3078–3085.
12. Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: A report from children's oncology group. Blood 2012;120:1581–1588.
13. San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C, Ramos F, Calmuntia MJ, Perez JJ, Gonzalez M, et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001;98:1746–1751.
14. Rawstron AC, Bottcher S, Letestu R, Villamor N, Fazi C, Kartsios H, de Tute RM, Shingles J, Ritgen M, Moreno C, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia 2013;27:142–149.
15. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the medical research council myeloma IX study. J Clin Oncol 2013;31:2540–2547.
16. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017–4023.
17. Wood BL. Flow cytometric monitoring of residual disease in acute leukemia. Methods Mol Biol 2013;999:123–136.
18. Clinical and Laboratory Standards Institute. Clinical Flow Cytometric Analysis of Neoplastic Hematolymphoid Cells; Approved Guideline, 2nd ed. CLSI Document H43-A2. 2007. p 27.
19. Kalina T, Flores-Montero J, van der Velden VH, Martin-Ayuso M, Bottcher S, Ritgen M, Almeida J, Lhermitte L, Asnafi V, Mendonca A, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia 2012;26:1986–2010.
20. Wood BL, Borowitz MJ. The flow cytometric evaluation of hematopoietic neoplasia. In: Clinical Diagnosis and Management by Laboratory Methods (Henry). Philadelphia, PA: W.B. Saunders; 2010.
21. Wood B. Multicolor immunophenotyping: Human immune system hematopoiesis. Methods Cell Biol 2004;75:559–576.
22. Krampera M, Perbellini O, Vincenzi C, Zampieri F, Pasini A, Scupoli MT, Guarini A, Propris D, Coustan-Smith MSE. Campana D, et al. Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica 2006;91:1109–1112.
23. Kern W, Schoch C, Haferlach T, Schnittger S. Monitoring of minimal residual disease in acute myeloid leukemia. Crit Rev Oncol Hematol 2005;56:283–309.
24. Feller N, van der Velden VH, Brooimans RA, Boeckx N, Preijers F, Kelder A, de Greef I, Westra G, Te Marvelde JG, Aerts P, et al. Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting. Blood Cancer J 2013;3:e129.
25. Roshal M, Fromm JR, Winter S, Dunsmore K, Wood BL. Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: Implications for minimal residual disease detection. Cytometry B Clin Cytom 2010;78B:139–146.
26. Langebrake C, Brinkmann I, Teigler-Schlegel A, Creutzig U, Griesinger F, Puhlmann U, Reinhardt D. Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring. Cytometry B Clin Cytom 2005;63B:1–9.
27. Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T, Kern W. Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings. Cytometry B Clin Cytom 2004;62B:25–38.
28. Baer MR, Stewart CC, Dodge RK, Leget G, Sule N, Mrozek K, Schiffer CA, Powell BL, Kolitz JE, Moore JO, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: Implications for residual disease detection (cancer and leukemia group B study 8361). Blood 2001;97:3574–3580.
29. Dworzak MN, Gaipa G, Schumich A, Maglia O, Ratei R, Veltroni M, Husak Z, Basso G, Karawajew L, Gadner H, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-study group. Cytometry B Clin Cytom 2010;78B:147–153.
30. Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, Faini A, Veltroni M, Husak D, Schumich A, et al. Prednisone induces immunophenotypic modulation of cd10 and cd34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom 2008;74B:150–155.
31. Gaipa G, Basso G, Maglia O, Leoni V, Faini A, Cazzaniga G, Bugarin C, Veltroni M, Michelotto B., Ratei R, et al. Drug-induced immunophenotypic modulation in childhood ALL: Implications for minimal residual disease detection. Leukemia 2005;19:49–56.
32. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–1518.
33. Sandes AF, Kerbauy DM, Matarraz S, Chauffaille Mde L, López A, Orfao A, Yamamoto M. Combined flow cytometric assessment of cd45, HLA-DR, cd34, and cd117 expression is a useful approach for reliable quantification of blast cells in myelodysplastic syndromes. Cytometry B Clin Cytom 2013;84B:157–166.
34. Wangen JR, Eidenschink Brodersen L, Stolk TT, Wells DA, Loken MR. Assessment of normal erythropoiesis by flow cytometry: Important considerations for specimen preparation. Int J Lab Hematol 2014;36:184–196.
35. Loken MR, Chu SC, Fritschle W, Kalnoski M, Wells DA. Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom 2009;76B:27–36.
36. Mathis S, Chapuis N, Borgeot J, Maynadié M, Fontenay M, Béné MC, Guy J, Bardet V. Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy. Cytometry B Clin Cytom 2015;88B:101–109.
37. Bjorklund E, Matinlauri I, Tierens A, Axelsson S, Forestier E, Jacobsson S, Ahlberg AJ, Kauric G, Mantymaa P, Osnes L, et al. Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment. J Pediatr Hematol Oncol 2009;31:406–415.
38. Dworzak MN, Gaipa G, Ratei R, Veltroni M, Schumich A, Maglia O, Karawajew L, Benetello A, Potschger U, Husak Z, et al. Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible. Cytometry B Clin Cytom 2008;74B:331–340.
39. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, Pui CH, Campana D. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120:5173–5180.
40. Salipante SJ, Fromm JR, Shendure J, Wood BL, Wu D. Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing. Mod Pathol 2014;27:1438–1446.
41. Wu D, Emerson RO, Sherwood A, Loh ML, Angiolillo A, Howie B, Vogt J, Rieder M, Kirsch I, Carlson C, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res 2014;20:4540–4548.
42. Wu D, Sherwood A, Fromm JR, Winter SS, Dunsmore KP, Loh ML, Greisman HA, Sabath DE, Wood BL, Robins H. High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012;4:134ra63.
43. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014;123:3073–3079.